IF0 Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.21 |
| 52 Week High | US$2.62 |
| 52 Week Low | US$0.75 |
| Beta | 2.22 |
| 1 Month Change | 20.50% |
| 3 Month Change | -47.61% |
| 1 Year Change | -2.03% |
| 3 Year Change | -16.61% |
| 5 Year Change | -81.75% |
| Change since IPO | -90.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| IF0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 23.7% | 0.8% | 2.6% |
| 1Y | -2.0% | -14.2% | 14.9% |
Return vs Industry: IF0 exceeded the German Biotechs industry which returned -14.8% over the past year.
Return vs Market: IF0 underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| IF0 volatility | |
|---|---|
| IF0 Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: IF0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IF0's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 74 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IF0 fundamental statistics | |
|---|---|
| Market cap | €103.44m |
| Earnings (TTM) | -€46.06m |
| Revenue (TTM) | €165.79k |
623.9x
P/S Ratio-2.2x
P/E RatioIs IF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IF0 income statement (TTM) | |
|---|---|
| Revenue | €165.79k |
| Cost of Revenue | €3.32m |
| Gross Profit | -€3.15m |
| Other Expenses | €42.91m |
| Earnings | -€46.06m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -0.68 |
| Gross Margin | -1,900.76% |
| Net Profit Margin | -27,784.96% |
| Debt/Equity Ratio | 0% |
How did IF0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/03 00:20 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InflaRx N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Madhu Kumar | B. Riley Securities, Inc. |